Can Crestor cause hair loss in women? It is a question many women ask after noticing increased shedding or thinning shortly after starting rosuvastatin. Crestor (rosuvastatin) is a widely prescribed statin used to lower LDL cholesterol and reduce cardiovascular risk. Alopecia is listed as a rare adverse reaction in the rosuvastatin Summary of Product Characteristics, affecting fewer than 1 in 1,000 people. However, the evidence for a direct causal link remains limited. This article explores what the evidence says, other potential causes of hair loss in women, and when to seek advice from your GP or pharmacist.
Summary: Crestor (rosuvastatin) lists alopecia as a rare adverse reaction affecting fewer than 1 in 1,000 people, but direct evidence of a causal link in women specifically remains limited.
- Alopecia is classified as a rare adverse reaction to rosuvastatin in the UK Summary of Product Characteristics (SmPC), based largely on spontaneous pharmacovigilance reports rather than clinical trial data.
- Hair loss is recognised as a rare class effect across statins, acknowledged by the British National Formulary (BNF); it is not unique to Crestor.
- Common alternative causes of hair loss in women include hypothyroidism, iron deficiency, PCOS, and telogen effluvium triggered by stress or illness.
- Do not stop taking Crestor without first consulting your GP or pharmacist, as abrupt discontinuation may increase cardiovascular risk.
- Suspected side effects, including hair loss, can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.
- If a drug-related cause is confirmed, your GP may consider switching to an alternative statin or adjusting your dose in line with NICE NG238 and SPS statin intolerance guidance.
Table of Contents
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
Does Crestor Cause Hair Loss in Women?
Alopecia is listed as a rare adverse reaction to Crestor (rosuvastatin) in its UK SmPC, affecting fewer than 1 in 1,000 people, but robust clinical evidence of a direct causal link in women is lacking.
Experiencing these side effects? Our pharmacists can help you navigate them →
Crestor is the brand name for rosuvastatin, a widely prescribed statin used to lower LDL cholesterol and reduce the risk of cardiovascular disease. It works by inhibiting HMG-CoA reductase, an enzyme involved in cholesterol synthesis in the liver, thereby reducing the production of low-density lipoprotein (LDL) cholesterol.
Hair loss, medically known as alopecia, is listed in the rosuvastatin Summary of Product Characteristics (SmPC), available via the Electronic Medicines Compendium (emc), as a rare adverse reaction (affecting fewer than 1 in 1,000 people). Alopecia is similarly recognised across the statin drug class as a rare adverse effect. It is important to note, however, that evidence of a direct causal link between rosuvastatin and hair loss remains limited, and the association is based largely on spontaneous reports and pharmacovigilance data rather than robust clinical trial evidence.
Women may be particularly attentive to changes in hair density or texture, and it is entirely understandable to question whether a new medication could be responsible. There is no strong, consistent clinical evidence directly linking Crestor to significant hair loss in women specifically. Individual responses to medicines can vary, and any noticeable change in hair health after starting a new medicine warrants discussion with a healthcare professional.
If you have recently started taking Crestor and noticed increased hair shedding or thinning, keep a record of when the changes began relative to when you started the medication. This information will be valuable when speaking to your GP or pharmacist.
Sources: rosuvastatin (Crestor) SmPC – emc/MHRA; NHS: Hair loss (alopecia).
Not sure if this is normal? Chat with one of our pharmacists →
| Side Effect | Frequency | Severity | Management |
|---|---|---|---|
| Alopecia (hair loss) — rosuvastatin (Crestor) | Rare: fewer than 1 in 1,000 people (per SmPC/MHRA) | Mild to moderate; usually reversible on discontinuation | Discuss with GP before stopping; consider switching statin or dose adjustment |
| Alopecia — statin class effect (e.g., atorvastatin, pravastatin) | Rare; recognised class effect per BNF | Mild; comparative risk between statins not reliably established | GP may trial alternative statin per NICE NG238 and SPS statin intolerance guidance |
| Hair loss due to hypothyroidism (differential diagnosis) | Common cause of diffuse hair loss in women | Moderate; treatable once identified | GP to arrange TSH blood test; treat underlying thyroid condition |
| Hair loss due to iron deficiency / telogen effluvium | Common; strongly associated with low ferritin | Moderate; typically reversible with treatment | GP to arrange FBC and serum ferritin; iron supplementation if deficient |
| Hair loss due to other medicines (e.g., anticoagulants, beta-blockers, SSRIs, oral contraceptives) | Varies by drug; recognised adverse effects | Mild to moderate | Pharmacist to review full medication list; GP to assess alternative options |
| Hair loss due to PCOS or androgen excess | Common cause of androgenetic alopecia in women | Moderate; may be progressive without treatment | GP to arrange hormonal profile; dermatology or endocrinology referral if indicated |
| Scalp inflammation or scarring alopecia (red flag) | Uncommon but clinically significant | Potentially severe; may cause permanent hair loss | Prompt dermatology referral if scalp pain, redness, scaling, pustules, or scarring present |
What the Evidence Says About Statins and Hair Thinning
Evidence linking statins to hair thinning is modest, based mainly on pharmacovigilance reports and case studies; the BNF recognises alopecia as a rare statin class effect, but no conclusive mechanism has been demonstrated in human trials.
The relationship between statins and hair loss has been explored in a limited number of studies and case reports, but the overall evidence base remains modest. Pharmacovigilance databases — including those maintained by the European Medicines Agency (EMA) and the MHRA's Yellow Card scheme — have recorded sporadic reports of hair thinning associated with statin use. The British National Formulary (BNF) acknowledges alopecia as a recognised, albeit uncommon, class effect of statins.
One proposed mechanism relates to statins' effect on cholesterol metabolism. Cholesterol is a precursor to steroid hormones, including androgens, which play a role in hair follicle cycling. By reducing cholesterol synthesis, statins may theoretically influence androgen levels or disrupt the normal anagen (growth) phase of the hair cycle. However, this mechanism has not been conclusively demonstrated in human clinical trials, and the evidence remains largely theoretical or based on case reports.
Some points worth noting:
-
Comparative risk across different statins (for example, rosuvastatin versus atorvastatin or pravastatin) has not been reliably established in high-quality studies; any differences in propensity to cause hair-related side effects between individual statins should be regarded as uncertain.
-
Dose and duration of statin therapy may influence whether hair changes occur, though robust dose–response data in humans are lacking.
-
Individual susceptibility may vary, but the contribution of specific genetic factors has not been well characterised in clinical research.
Where hair loss has been reported in association with statin use, cases have often resolved after discontinuation or switching to an alternative statin, though data on reversibility are limited. Overall, statin-associated hair loss appears to be a rare phenomenon rather than a predictable or common adverse effect.
Sources: BNF – Rosuvastatin and statin class effects; EMA EPAR – Crestor (rosuvastatin); MHRA Yellow Card pharmacovigilance data.
Other Medicines and Health Conditions That Affect Hair Loss
Hypothyroidism, iron deficiency, and PCOS are among the most common treatable causes of hair loss in women and should be excluded before attributing shedding to Crestor.
Before attributing hair loss solely to Crestor, it is essential to consider the wide range of other medicines and underlying health conditions that are well-established causes of alopecia in women. Hair loss is a multifactorial condition, and identifying the correct cause is important for appropriate management.
Medicines commonly associated with hair loss include:
-
Anticoagulants such as warfarin and heparin
-
Antithyroid drugs (e.g., carbimazole)
-
Antidepressants, including some SSRIs
-
Oral contraceptives and hormonal therapies
-
Retinoids (vitamin A derivatives)
-
Certain antihypertensives, including beta-blockers
-
Sodium valproate
-
Cytotoxic (chemotherapy) agents
Health conditions that frequently cause hair thinning in women include:
-
Hypothyroidism — an underactive thyroid is one of the most common and treatable causes of diffuse hair loss in women
-
Iron deficiency — low ferritin levels are strongly associated with telogen effluvium (diffuse shedding); a full blood count and ferritin measurement are usually the first-line investigations
-
Polycystic ovary syndrome (PCOS) — androgen excess can cause androgenetic alopecia
-
Autoimmune conditions such as alopecia areata or lupus
-
Nutritional deficiencies, including low zinc or inadequate protein intake; biotin deficiency is uncommon in the UK and routine testing is not recommended unless specific risk factors are present
Stress, significant weight loss, and major illness can also trigger telogen effluvium — a temporary but distressing form of diffuse hair shedding that typically occurs two to three months after a triggering event.
Given the breadth of potential causes, a thorough clinical assessment is always recommended before concluding that Crestor is responsible for hair changes.
Sources: NICE CKS – Female pattern hair loss; Alopecia areata; PCDS – Diffuse hair loss (telogen effluvium); NHS: Hair loss (alopecia).
When to Speak to Your GP or Pharmacist
Contact your GP if hair loss is significant, sudden, patchy, or accompanied by other symptoms; initial blood tests including FBC, ferritin, and TSH help exclude common treatable causes.
If you are taking Crestor and have noticed changes in your hair, seek professional advice rather than stopping your medication without guidance. Statins are prescribed for important cardiovascular reasons, and discontinuing them without medical supervision could carry health risks.
You should contact your GP if:
-
Hair loss is significant, sudden, or progressing rapidly
-
You notice patchy hair loss rather than diffuse thinning
-
You have signs that may suggest scarring or inflammatory scalp disease — such as scalp pain or tenderness, redness, scaling, pustules, or visible scarring — as these warrant prompt dermatology referral
-
Hair loss is accompanied by other symptoms such as fatigue, weight changes, or skin changes (which may suggest an underlying thyroid or autoimmune condition)
-
You have been taking Crestor for several months and hair changes have persisted or worsened
-
You are concerned about the impact on your quality of life or mental wellbeing
Your GP may arrange initial blood tests including:
-
Full blood count (FBC)
-
Serum ferritin
-
Thyroid-stimulating hormone (TSH)
-
Additional tests (e.g., B12, folate, hormonal profile) if clinically indicated
These investigations help to exclude common, treatable causes of hair loss before a drug-related cause is considered.
Your pharmacist can help by:
-
Reviewing your full medication list to identify other potential contributors
-
Advising on whether a GP referral is appropriate
-
Providing information on the Yellow Card reporting scheme if you suspect a drug side effect
If a drug-related cause is suspected, your GP may consider switching to an alternative statin or adjusting your dose, always weighing the cardiovascular benefits against the reported side effect. Do not stop taking Crestor without first speaking to your GP or pharmacist, as abrupt discontinuation may increase your cardiovascular risk.
Sources: NICE CKS – Female pattern hair loss; Alopecia areata; PCDS – Scarring alopecia red flags; NHS: Hair loss (alopecia).
Managing Hair Loss While Taking Crestor
Management options include switching to an alternative statin, dose adjustment, or non-statin alternatives such as ezetimibe, all guided by NICE NG238 and SPS statin intolerance guidance.
If investigations confirm that no underlying medical condition is responsible for your hair loss, and a possible link to Crestor is suspected, there are several practical steps that can be taken in collaboration with your healthcare team.
Medical management options may include:
-
Switching statins — your GP may consider trialling an alternative statin such as atorvastatin or pravastatin to see whether hair loss improves, whilst maintaining cardiovascular protection. NICE guideline NG238 (Cardiovascular disease: risk assessment and reduction, including lipid modification) and Specialist Pharmacy Service (SPS) guidance on managing statin intolerance provide a framework for switching statins safely.
-
Dose adjustment — in some cases, a lower dose may reduce the likelihood of side effects whilst still providing therapeutic benefit, as discussed in SPS statin intolerance guidance.
-
Non-statin alternatives — if statin intolerance is confirmed and switching does not resolve the problem, your GP may consider non-statin lipid-lowering options such as ezetimibe, in line with NICE NG238.
-
Addressing nutritional deficiencies — ensuring adequate intake of iron, zinc, and protein supports healthy hair growth and may help mitigate shedding.
Supportive self-care measures include:
-
Using gentle, sulphate-free shampoos and avoiding excessive heat styling
-
Avoiding tight hairstyles that place traction on the scalp
-
Eating a balanced diet rich in leafy greens, lean proteins, and healthy fats
-
Managing stress through regular physical activity, adequate sleep, and mindfulness practices
For women experiencing significant distress related to hair loss, referral to a dermatologist with a specialist interest in trichology may be appropriate. NICE guidance recommends a holistic approach that addresses both the physical and psychological impact of hair loss.
In some cases, topical minoxidil — available over the counter in the UK — may be considered as a treatment for androgenetic (female pattern) hair loss. It is not indicated for telogen effluvium. Important precautions include:
-
Avoid in pregnancy and whilst breastfeeding
-
An initial increase in shedding may occur in the first few weeks of use; this is usually temporary
-
Potential side effects include scalp irritation and, rarely, unwanted facial hair growth
-
Always discuss with a healthcare professional before starting minoxidil
Sources: NICE NG238 – Cardiovascular disease: risk assessment and reduction (lipid modification); SPS – Managing statin intolerance / Switching statins; NHS: Minoxidil information; NICE CKS – Female pattern hair loss.
MHRA Reporting and Patient Safety Guidance
Suspected side effects from Crestor, including hair loss, should be reported to the MHRA via the Yellow Card scheme; you do not need to be certain of causation to submit a report.
The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK body responsible for monitoring the safety of medicines and medical devices. If you believe you have experienced a side effect from Crestor — including hair loss — you are encouraged to report it through the Yellow Card scheme, which can be accessed online at yellowcard.mhra.gov.uk, via the Yellow Card app, or through your GP or pharmacist.
Reporting suspected side effects is an important part of post-marketing pharmacovigilance. Even if a causal link between Crestor and your hair loss is uncertain, submitting a Yellow Card report contributes to the national evidence base and helps the MHRA identify patterns that may not have been apparent during clinical trials. You do not need to be certain that the medicine caused the side effect — a suspicion is sufficient to make a report. Healthcare professionals are also encouraged to report suspected adverse drug reactions through the same Yellow Card system.
The MHRA regularly reviews safety data for all licensed medicines, including statins, and updates prescribing information when new safety signals are identified. The rosuvastatin (Crestor) SmPC, available via the emc, lists alopecia as a rare adverse reaction; readers are encouraged to consult the current SmPC for the most up-to-date prescribing information.
From a patient safety perspective, the key messages are:
-
Do not stop Crestor without medical advice
-
Report suspected side effects via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk)
-
Seek a thorough clinical assessment to exclude other causes of hair loss
-
Engage with your GP or pharmacist to find the most appropriate and safe management plan tailored to your individual circumstances
With the right support, most women are able to manage any hair-related concerns whilst continuing to benefit from the cardiovascular protection that statin therapy provides.
Sources: MHRA Yellow Card scheme (yellowcard.mhra.gov.uk); rosuvastatin (Crestor) SmPC – emc/MHRA; EMA EPAR – Crestor (rosuvastatin).
Frequently Asked Questions
How common is hair loss as a side effect of Crestor?
Hair loss (alopecia) is classified as a rare side effect of Crestor (rosuvastatin), meaning it affects fewer than 1 in 1,000 people who take it. The association is based mainly on spontaneous reports to pharmacovigilance databases rather than large clinical trials, so it is not considered a predictable or common adverse effect.
Will my hair grow back if Crestor is causing the thinning?
In cases where statin-associated hair loss has been reported, shedding has often resolved after discontinuing or switching to a different statin, though data on reversibility are limited. You should discuss any hair changes with your GP before making any changes to your medication, as stopping Crestor without guidance may increase your cardiovascular risk.
Is hair loss from Crestor more likely in women than in men?
There is no strong clinical evidence to suggest that Crestor causes hair loss more frequently in women than in men. Women may be more likely to notice or report changes in hair density, and they are also more susceptible to other common causes of hair thinning such as thyroid disorders and iron deficiency, which should be excluded first.
What is the difference between Crestor and atorvastatin when it comes to hair loss?
Alopecia is recognised as a rare class effect across all statins, including both rosuvastatin (Crestor) and atorvastatin, so neither has been reliably shown to be safer than the other in terms of hair-related side effects. If you experience hair loss on one statin, your GP may consider switching to another, but any improvement cannot be guaranteed.
Can I use minoxidil for hair loss while taking Crestor?
Topical minoxidil is available over the counter in the UK and may be considered for female pattern (androgenetic) hair loss, but it is not indicated for telogen effluvium or drug-related shedding. Always speak to your GP or pharmacist before starting minoxidil, particularly if you are pregnant, breastfeeding, or taking other medicines.
How do I report a suspected hair loss side effect from Crestor to the MHRA?
You can report a suspected side effect from Crestor, including hair loss, through the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk, via the Yellow Card app, or through your GP or pharmacist. You do not need to be certain that Crestor caused the problem — a suspicion is enough, and your report helps build the national evidence base for medicine safety.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
